

Ref. No.: WOCK/SEC/SE/2025-26/011

29<sup>th</sup> May, 2025

<b>BSE Limited</b> Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <b><u>Scrip Code: 532300</u></b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <b><u>NSE Symbol: WOCKPHARMA</u></b>
--	---

Dear Sir/ Madam,

**Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release**

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Audited Financial Results (Standalone and Consolidated) for the quarter and the financial year ended 31<sup>st</sup> March, 2025.

A copy of the same will also be uploaded on the Company's website [www.ockhardt.com](http://www.ockhardt.com)

Kindly take the same on record please.

Thanking you,  
For **Wockhardt Limited**



**Rashmi Mamtura**  
**Company Secretary**

**Encls: A/a**

Mumbai, May 29<sup>th</sup>, 2025

- **Wockhardt FY 25 EBITDA jumps to Rs.418 crore; growth by 67%**
- **Zaynich: Filed for approval in India in March 2025 and planned for filing in USA by August 2025**
- **Miqnaf approved and launched on May 27,2025 in India**

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4<sup>th</sup> Quarter Results for Financial Year 2024-25, today.

FY25 REVENUE	FY 25 EBITDA
<b>3033 Cr</b>	<b>418 Cr</b>
 <b>5% Gr</b>	 <b>67% Gr</b>

YoY growth of 5% in revenue in FY25, Revenue for FY25 of INR 3,033 Cr compared to INR 2,879 Cr in the previous year. YoY growth of 67% in EBITDA in FY25, EBITDA for FY25 of INR 418 Cr compared to INR 251 Cr in the previous year.

Revenue for Q4FY25 of INR 743 Cr compared to INR 750 Cr in the previous year. QoQ growth of 13% in EBITDA in Q4FY25, EBITDA for Q4FY25 of INR 79 Cr compared to INR 70 Cr in the previous year.

## Novel Antibiotics:

**ZAYNICH® (Zidebactam/Cefepime, WCK 5222) Filed for approval in India in March 2025 and planned for filing in USA by August 2025**



Following the completion of the Global, pivotal, registration-enabling, Phase III study in hospitalized complicated urinary tract infection (cUTI) patients, Wockhardt's Zaynich® has demonstrated the highest-ever efficacy achieving a clinical cure rate of 96.8%.

The study enrolled 529 patients with complicated urinary tract infection (cUTI) and Acute Pyelonephritis (AP) and was conducted in US, Europe, LATAM, China, India, spanning 64 sites.

In this study, Zaynich® demonstrated superiority over gold standard meropenem, achieving a composite clinical and microbiology cure rate of 89.0% vs 68.4% respectively. These results were based on primary endpoints defined by both the US FDA and EMA.

The combined efficacy of Zaynich® is the highest ever recorded among recently approved novel antibiotics developed in more than a decade. The outcome of this study reflects the impact of Zaynich's novel  $\beta$ -lactam enhancer mechanism of action. Additionally, Zaynich® was well-tolerated and showed a safety profile consistent with  $\beta$ -lactam class of antibiotics, comparable to meropenem.

This study is NDA-enabling, based on which marketing authorization applications will be made to global health authorities including India, US, EMA and MHRA. For India, the DCGI filing for commercial approval was submitted on 31st March 2025. In parallel, preparations for the U.S. New Drug Application (NDA) filing are progressing, marked by the successful completion of a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). Filing in USA is expected by August 2025

**Compassionate Use:** We have treated 51 patients, including three US Patients, under compassionate use, after receiving approval from DCGI and US FDA. Use of Zaynich® resulted



**3<sup>rd</sup> US CANCER PATIENT**

ZAYNICH® successfully **RESOLVED**  
**DRUG RESISTANT LIFE THREATENING**  
**BLOOD STREAM INFECTION**

Stabilized Patient's condition  
Marking a full recovery from  
untreatable infection

in >95% cure and was found to be safe even when administered up to 95 days.



**51 LIVES SAVED**


Under Compassionate Use

Including **3** from US

Meropenem Resistance Clinical Trial as well as several patients successfully treated under compassionate use in India and US, have re-affirmed the life-saving feature of Zaynich®

## **MIQNAF® NAFITHROMYCIN, approved and launched on May 27 2025, in India**


Wockhardt proudly announces the launch of India's First Indigenous Respiratory Antibiotic on May 27 2025 - A Historic Step in the fight against Antimicrobial Resistance and a transformative moment in India's Antibiotic Research landscape.



WOCKHARDT  
**LAUNCHES MIQNAF®**  
FOR THE TREATMENT OF  
**COMMUNITY ACQUIRED**  
**BACTERIAL PNEUMONIA**

This breakthrough ends a wait of over 30 years for a new antibiotic in the macrolide class, at a time when the world faces an escalating antimicrobial resistance (AMR) crisis.

MIQNAF is specifically designed to target both typical and atypical pathogens, offering new hope against multi-drug-resistant infections with its Ultra Short Course, three day oral therapy.



**97%**  
Success Rate in  
Community Acquired  
Pneumonia

**Ultra Short**  
**3-Day**  
Treatment

Approved for Community-Acquired Bacterial Pneumonia (CABP) caused by resistant Respiratory Pathogens, the drug addresses a leading global cause of death, which claims over 2 million lives annually.

With India carrying 23% of the world's pneumonia burden, MIQNAF's development comes as a critical solution to current treatment gaps and rising resistance to older antibiotics like azithromycin and co-amoxiclav.



Coverage includes pneumococci  
**RESISTANT** to Azithromycin  
& Amoxicillin/clavulanate



Obviates need for  
HOSPITALIZATION



HIGH SAFETY  
7 TOLERABILITY

MIQNAF offers high safety and tolerability, with minimal gastrointestinal effects, no significant drug interactions, and no dietary restrictions.

In India, MIQNAF is being strategically introduced to specialists, specifically chest physicians and consulting physicians. To support this targeted approach, a dedicated MIQNAF team has been established to engage with these medical professionals.

The journey of MIQNAF has spanned 14 years of rigorous research and development including clinical trials in the US, Europe, and India.



Company won the prestigious BIRAC INNOVATOR AWARD 2024 from the Government of India for the highest level of innovation and research that led to successful development of MIQNAF

MIQNAF launch signals India's leadership in the global response to antimicrobial resistance.

Wockhardt plans to expand MIQNAF's reach to Saudi Arabia, Latin America, Southeast Asia, and Africa in the near and midterm future.

**ERTAPENEM-ZIDEACTAM (WCK 6777)**: WCK 6777 is a once-a-day,  $\beta$ -lactam enhancer-based combination being developed for outpatient parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is the only drug in the global antibiotic pipeline designed for OPAT.

WCK 6777 is active against entire range of meropenem-resistant Gram-negative pathogens generally encountered in community as well as in hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections.



Recognizing its potential to meet significant unmet medical needs, the US FDA has granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI).


Results from Phase I study (52 subjects) conducted by National Institutes of Health, US, demonstrated a promising safety profile, with WCK 6777 being well-tolerated, and no serious

or unexpected adverse events reported. This study paves the way for advancement of WCK 6777 into Phase II trial.

**EMROK/ EMROK O:** Emrok has successfully treated >100,000 patients to date. It is currently undergoing the registration process in 9 countries within emerging markets and anticipates receiving approvals within the next 6 to 12 months.





## Biosimilars Business Highlights:



Our Insulin and Glargine business has demonstrated remarkable and sustainable growth driven by increasing volumes accelerating our presence and reach across Emerging Markets. Likewise in India, our domestic biotech business is poised for substantial growth. Upgradation and expansion of biosimilar facilities underway to meet existing

demand as well as our entry into newer emerging markets. This positions us well for scaling the Biotech business growth to the next level, strengthening our commitment to meeting global healthcare needs and advancing our leadership in diabetes care

## Business Highlights



**India Branded Business** stood at Rs.95 crore in Q4FY25 and for FY25 the revenue was Rs. 456 crore.

**UK Business** stood at Rs.292 crore in Q4FY25 with a growth of 9% and for FY25 the revenue was Rs. 1,169 crore with a growth of 12%.

**Irish Business** stood at Rs.47 crore in Q4FY25 and for FY25 the revenue was Rs. 181 crore.

## New Products Launch FY'24-25:

- 7 Filings and 6 Launches in Wockhardt UK
- 1 Filing and 6 New launches in Ireland
- Biosimilars & NCE - 19 Filings & 5 Approvals
- EMROK/EMROK O - Registration has been filed in 9 countries of ROW & other Markets

### UK FY'25

7 Filing  
6 New launches

### Pinewood FY'25

1 Filing  
6 New launches

### BIOSIMILARS & NCE

19 Filings & 5 Approvals

### EMROK/ & O - EM

9 Countries Approval in next 6-9 months



## Intellectual Property Update:

- 4 patents were filed during the quarter ended 31<sup>st</sup> March 2025 and the cumulative filings till date are 3273.
- The company was granted 4 patents during the quarter and now holds 848 patents.
- India - 6 NCE Patents Granted till Mar'25

### PATENTS

Filings till Date : 3273  
Patents Granted : 848

### NCE PATENTS

Patents Granted : 6 India

## Financial Performance:

Particulars	Q4 FY25	Q4 FY24	Q3 FY25	FY25	FY24
	Jan - Mar 2025	Jan - Mar 2024	Oct - Dec 2024	Apr - Mar 2025	Apr - Mar 2024
<b>Total Revenue</b>	<b>743</b>	<b>750</b>	<b>725</b>	<b>3,033</b>	<b>2,879</b>
<b>EBITDA before R&amp;D</b>	<b>113</b>	<b>103</b>	<b>131</b>	<b>537</b>	<b>384</b>
<b>EBITDA % to Sales</b>	<b>15.2%</b>	<b>13.8%</b>	<b>18.1%</b>	<b>17.7%</b>	<b>13.3%</b>
<b>R&amp;D</b>	<b>34</b>	<b>33</b>	<b>31</b>	<b>119</b>	<b>132</b>
<b>R&amp;D % to Sales</b>	<b>4.6%</b>	<b>4.4%</b>	<b>4.2%</b>	<b>3.9%</b>	<b>4.6%</b>
<b>EBITDA</b>	<b>79</b>	<b>70</b>	<b>100</b>	<b>418</b>	<b>251</b>
<b>EBITDA Margins %</b>	<b>10.7%</b>	<b>9.4%</b>	<b>13.8%</b>	<b>13.8%</b>	<b>8.7%</b>
<b>Exceptional Items</b>	-	-	-	-	(14)
<b>Loss on sale of property, plant &amp; equipment #</b>	-	(123)	-	-	(131)
<b>PBT</b>	<b>(22)</b>	<b>(180)</b>	<b>21</b>	<b>(16)</b>	<b>(420)</b>
<b>Profit After Tax</b>	<b>(45)</b>	<b>(177)</b>	<b>20</b>	<b>(57)</b>	<b>(472)</b>
<b>PAT Margins %</b>	<b>-6.1%</b>	<b>-23.6%</b>	<b>2.8%</b>	<b>-1.9%</b>	<b>-16.4%</b>

# In Q4FY24 and FY 24, the company had recognized an impairment loss of Rs. 79 crore on assets held for sale. Additionally, the company had incurred a loss of Rs. 42 crore on the sale of property, plant, and equipment attributable to the restructuring of the company's US operations.



**PRESS RELEASE**



**Wockhardt Limited**  
Registered Office:  
D-4, MIDC, Chikalthana  
Chhatrapati Sambhajnagar  
431006, India  
Tel.: +91-22-2653 4444  
CIN: L24230MH1999PLC120720

## About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing around ~2900 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 77% of its global revenues coming from international businesses.



DRUG DISCOVERY PROGRAMME  
**USFDA QIDP STATUS : 6 ANTI-BACTERIALS**